Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1391-1400 of 1,873) with videos related to

Pageof 188
Sort By:
European Heart Journal|June 26, 2023
Stroke in patients with heart failure and reduced or preserved ejection fractionMingming Yang, Toru Kondo, Jawad H Butt, et al.
European Heart Journal|May 28, 2026
Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysisRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Journal of the American College of Cardiology|January 10, 2019
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and WomenPooja Dewan, Rasmus Rørth, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|January 2, 2025
Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 TrialsHenri Lu, Toru Kondo, Brian L Claggett, et al.
JACC. Heart Failure|November 21, 2024
Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF TrialFinnian R Mc Causland, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure|May 29, 2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trialScott D Solomon, Rudolf A de Boer, David DeMets, et al.
Circulation. Heart Failure|October 22, 2021
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection FractionMasatoshi Minamisawa, Brian Claggett, Kota Suzuki, et al.
European Journal of Heart Failure|January 6, 2022
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failureFinnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
European Journal of Heart Failure|September 2, 2022
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trialOtavio Berwanger, Marc Pfeffer, Brian Claggett, et al.
JAMA Cardiology|February 17, 2021
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection FractionDavid D Berg, Pardeep S Jhund, Kieran F Docherty, et al.
Pageof 188

Showing results (1391-1400 of 1,873) with videos related to

Sort By:
Pageof 188
European Heart Journal|June 26, 2023
Stroke in patients with heart failure and reduced or preserved ejection fractionMingming Yang, Toru Kondo, Jawad H Butt, et al.
European Heart Journal|May 28, 2026
Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysisRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Journal of the American College of Cardiology|January 10, 2019
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and WomenPooja Dewan, Rasmus Rørth, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|January 2, 2025
Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 TrialsHenri Lu, Toru Kondo, Brian L Claggett, et al.
JACC. Heart Failure|November 21, 2024
Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF TrialFinnian R Mc Causland, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure|May 29, 2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trialScott D Solomon, Rudolf A de Boer, David DeMets, et al.
Circulation. Heart Failure|October 22, 2021
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection FractionMasatoshi Minamisawa, Brian Claggett, Kota Suzuki, et al.
European Journal of Heart Failure|January 6, 2022
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failureFinnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
European Journal of Heart Failure|September 2, 2022
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trialOtavio Berwanger, Marc Pfeffer, Brian Claggett, et al.
JAMA Cardiology|February 17, 2021
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection FractionDavid D Berg, Pardeep S Jhund, Kieran F Docherty, et al.
Pageof 188